Interferon regulatory factor 4 deletion protects against kidney inflammation and fibrosis in deoxycorticosterone acetate/salt hypertension

aDepartment of Anesthesiology, The First People's Hospital of Foshan, Foshan

bGuangdong Medical University, Zhanjiang

cDepartment of Anesthesiology, Foshan Women and Children Hospital

dDepartment of Anesthesiology, Affiliated Foshan Women and Children Hospital of Southern Medical University, Foshan

eDepartment of Anesthesiology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China

Correspondence to Hua Liang, Guangdong Medical University, Zhanjiang 524000, China. E-mail: [email protected]

Abbreviations: PI3K, phosphoinositide-3 kinase; CKD, chronic kidney disease; DMEM, Dulbecco's modified eagle medium; DOCA, deoxycorticosterone acetate; ECM, extracellular matrix; ESRD, end stage of renal disease; IRF-4, Interferon regulatory factor 4; PTEN, phosphatase and tensin homolog; SMA, anti-α-smooth muscle actin

Received 9 September, 2022

Revised 17 January, 2023

Accepted 3 February, 2023

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.jhypertension.com).

留言 (0)

沒有登入
gif